In patients with schizophrenia, there appear to be connections between longer duration of illness, raised levels of eotaxin, decreased telomere length, reduced gray matter volume, and impaired episodic memory.
Related content
Novel and emerging pharmacologic treatments for Schizophrenia
In this video Professor Christoph Correll discusses the challenges with available schizophrenia treatments & what clinicians should keep in mind when considering the emerging treatment options for schizophrenia.
14.11.2023
Schizophrenia
Summary of high-level clinical characteristics of currently approved as well as newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled study
The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
14.11.2023
Schizophrenia
Neurotransmitter pathways involved in current and novel mechanism-action schizophrenia treatments
LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.
14.11.2023
Schizophrenia